You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

66 Results
Guidelines and Advice
Status: Current
ID: GL MOTAC-4
Version: 3
Jun 2025
Drug
Other Name(s): Cytosar®
Quick Link(s):
Drug Monograph, Patient Info Sheet
Jul 2025
Regimen
Cancer Type:
Lung, 
Thymoma
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Drugs Used:
cyclophosphamide,
DOXOrubicin,
CISplatin
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Nov 2017
Regimen
Cancer Type:
Lung, 
Thymoma
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative, Adjuvant
Drugs Used:
CISplatin,
etoposide
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Nov 2017
Regimen
Cancer Type:
Gynecologic, 
Germ Cell
Show More Show more tags
, Show Less Show fewer tags
Intent: Adjuvant
Drugs Used:
CISplatin,
etoposide
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Nov 2017
Regimen
Cancer Type:
Breast
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
ODB - General Benefit
    capecitabine
Exceptional Access Program
    lapatinib - Second-Line treatment of HER2 positive metastatic breast cancer in combination with chemotherapy after previous exposure to trastuzumab based treatments, with specific criteria
Exceptional Access Program
    lapatinib - Treatment of HER-2 positive metastatic breast cancer when used in combination with chemotherapy after use of trastuzumab in patients who have an adverse drug reaction or contraindication to trastuzumab therapy
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
capecitabine,
lapatinib
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Jul 2025
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's High Grade, 
Lymphoma - Non-Hodgkin's Intermediate Grade
Show More Show more tags
, Show Less Show fewer tags
Intent: Curative, Palliative
Funding:
ODB - General Benefit
    etoposide - oral capsules
ODB - General Benefit (with Therapeutic Notes)
    procarbazine
ODB - General Benefit
    prednisone
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
cyclophosphamide,
etoposide,
procarbazine,
prednisone
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Nov 2017
Regimen
Cancer Type:
Hematologic, 
Leukemia - Acute Myeloid (AML)
Show More Show more tags
, Show Less Show fewer tags
Intent: Curative
Funding:
Exceptional Access Program
    midostaurin - First-line treatment of adult patients diagnosed with FLT3-mutated acute myeloid leukemia, in combination with specific standard induction followed by consolidation chemotherapy, according to clinical criteria
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
cytarabine,
midostaurin
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Jul 2025
Regimen
Cancer Type:
Hematologic, 
Multiple Myeloma
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Drugs Used:
cyclophosphamide
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Nov 2017
Statistical Reports
Nov 2017
Regimen
Cancer Type:
Endocrine, 
Adrenal
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Drugs Used:
cyclophosphamide,
vinCRIStine,
dacarbazine
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Nov 2017
Regimen
Cancer Type:
Endocrine, 
Adrenal
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Drugs Used:
DOXOrubicin,
etoposide,
CISplatin
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Nov 2017

Pages